Compare Gilead Sciences, Inc. (GILD) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Mongodb Inc — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Mongodb Inc trades at $331.85 (market cap $26.79B). The key difference: Gilead Sciences, Inc. is far larger — about 6.1× Mongodb Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| GILD | MDB | |
|---|---|---|
Market Cap | $163.51B | $26.79B |
Sector | Health | Technology |
52-Week High | $155.80 | $440.25 |
52-Week Low | $108.22 | $201.08 |
Enterprise Value | $178.05B | $24.39B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MongoDB (MDB) trades at $328.03, down 4.83% over 24 hours, with a bullish technical signal but bearish moving averages. Revenue growth is strong, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and AI-driven demand for database products highlight operational momentum, while negative cash flow and high valuation ratios present challenges.
The outlook is mixed: robust revenue growth and analyst optimism (81.81% buy ratings) support upside to the $400.39 consensus target, but profitability concerns and competitive pressures in cloud infrastructure pose risks. Investors should weigh strong top-line expansion against persistent losses and elevated multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
